Author(s):
Pratibha Tiwari, Prerna Tiwari, Pratixa Patel
Email(s):
tiwaripratibha.lc@gmail.com
DOI:
10.52711/2231-5691.2025.00029 
Address:
Pratibha Tiwari1*, Prerna Tiwari2, Pratixa Patel3
1,2ROFEL Shri G.M. Bilakhia College of Pharmacy, Vapi, Gujarat.
3Department of Pharmacology, ROFEL Shri G.M. Bilakhia College of Pharmacy, Vapi, Gujarat.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
This review evaluates the Covishield vaccine, which was developed by AstraZeneca and is produced in India by the Serum Institute, focusing on its effectiveness and potential side effects. The analysis employed various study designs, including test-negative case-control studies and cohort studies, to assess the vaccine's performance in preventing COVID-19 across diverse populations. The findings indicate that Covishield provides substantial protection, with a single dose offering approximately 49% effectiveness and two doses increasing the effectiveness to around 54% in preventing COVID-19 infection. Importantly, the vaccine demonstrates high effectiveness—about 95%—in preventing severe cases of COVID-19 that require oxygen therapy, highlighting its role in mitigating serious disease outcomes. Common side effects reported following vaccination include malaise, headache, fatigue, and fever. These symptoms generally onset 6-8 hours after vaccination and resolve within 24-100 hours. Additionally, some cardiovascular adverse events, such as tachycardia and hypertension, were noted, though their causal link to the vaccine remains unconfirmed. Overall, Covishield proves effective in reducing both the incidence of COVID-19 infections and the severity of the disease, with side effects that are typically manageable and transient.
Cite this article:
Pratibha Tiwari, Prerna Tiwari, Pratixa Patel. Effectiveness and Possible Side effects of the Covishield Vaccine in Preventing Covid-19. Asian Journal of Pharmaceutical Research. 2025; 15(2):176-2. doi: 10.52711/2231-5691.2025.00029
Cite(Electronic):
Pratibha Tiwari, Prerna Tiwari, Pratixa Patel. Effectiveness and Possible Side effects of the Covishield Vaccine in Preventing Covid-19. Asian Journal of Pharmaceutical Research. 2025; 15(2):176-2. doi: 10.52711/2231-5691.2025.00029 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-2-14
REFERENCES:
1. Gorbalenya AE, et al. Coronaviridae study group of the international committee on taxonomy of viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming its SARS-CoV-2. Nat Microbiol. 2020; 5:536–44.
2. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020; 323:709–10. https://doi.org/10.1001/jama.2020.1097.
3. WHO. World-health-organization coronavirus disease (COVID-19) outbreak; 2020 [accessed 2020 Jan 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
4. Srivastava N, et al. Global trends in epidemiology of coronavirus disease 2019 (COVID-19). In: Saxena SK, editor. Coronavirus disease 2019 (COVID-19): epidemiology, pathogenesis, diagnosis, and therapeutics. Singapore: Springer Singapore; 2020. p. 9–21.
5. Yadav T, et al. Recombinant vaccines for COVID-19. Hum Vaccin Immunother. 2020;16(12):2905-2912.
6. B. V. Naresh. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian J. Pharm. Res. 2020; 10(3):233-238. doi: 10.5958/2231-5691.2020.00040.4
7. Vaishnavi. K. Patil, Azam. Z. Shaikh. Corona (Covid - 19). Asian J. Pharm. Res. 2020; 10(4):275-285. doi: 10.5958/2231-5691.2020.00048.9
8. Sonia Mor, Prem Saini, Subhash Kumar Wangnoo, Tarunika Bawa. Worldwide spread of COVID-19 Pandemic and risk factors among Co-morbid conditions especially Diabetes Mellitus in India. Research J. Pharm. and Tech 2020; 13(5):2530-2532.
9. Sheila Menon FBSCH, Vidya Bhagat. Review of the impact Covid-19 has on the Psychosocial factors affecting Well-Being. Research Journal of Pharmacy and Technology. 2021; 14(6):3404-8.
10. Sameh Saber, Ahmed E. Khodir, Abdalkareem Omar Maghmomeh, Nehal A. Nouh, Ahmed M. El-Baz. COVID-19 Pandemic: current Challenges and future Perspectives. Research Journal of Pharmacy and Technology. 2022; 15(1):329-7.
11. Hyam Raouf Al-Hamamy. COVID-19: Immune response. Research Journal of Pharmacy and Technology. 2022; 15(1):467-0.
12. Zakarya, Al Zalak, Sahar Alfahoum, Razan Zohairee. Exploring COVID-19 Progression Patterns. Research Journal of Pharmacy and Technology. 2022; 15(3):1299-6.
13. Kandra Naga Vishnu, Praveen Kumar Uppala, Yakaiah Vangoori, Siva Naga Koteswara Rao Gudhanti. A Review on Covid 19 Pandemic and its Global Effects. Asian Journal of Pharmaceutical Research. 2021; 11(4): 242-6. doi: 10.52711/2231-5691.2021.00042
14. Ministry of Health and Family Welfare, Government of India. COVID-19 vaccines operational guidelines. Updated December 28, 2020. [Internet]. [cited 2021 Jul 14]. Available from: https://main.mohfw.gov.in/sites/default/files/COVID19VaccineOG111Chapter16.pdf.
15. Ministry of Health and Family Welfare, Government of India. CoWIN Dashboard [Internet]. [cited 2021 Jul 16]. Available from: https://dashboard.cowin.gov.in/.
16. World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). 2021. Available from: https://apps.who.int/iris/rest/bitstreams/1343289/retrieve.
17. Pramod S, et al. Effectiveness of Covishield vaccine in preventing Covid-19–A test-negative case-control study. Vaccine. 2022;40(24):3294-3297.
18. HFW_DCGI_emergency_use_authorisation_03012021_2.pdf. Available from: https://www.icmr.gov.in/pdf/press_realease_files/HFW_DCGI_energency_use_authorisation_03012021_2.pdf.
19. Mohandas S, et al. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model. iScience. 2021;24(2):102054.
20. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478.
21. Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269): 99-111.
22. Principles of Epidemiology Lesson 3 - Section 6; 2019. Available from: https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section6.html.
23. Ghosh S, et al. COVISHIELD (AZD1222) Vaccine effectiveness among healthcare and frontline workers of Indian Armed Forces: Interim results of VIN-WIN cohort study. Med J Armed Forces India. 2021;77.
24. Patil PB, et al. Review on Covishield and Covaxin Vaccine against COVID-19. Health. 2023;2:50-56.
25. Shrewastwa, M. K., Siddiqui, S., and Thapa, S. Assessment of booster dose's adverse effects of Covishield and Vero Cell vaccine among the staff and medical students of Nepalgunj Medical College. International Journal of Medical Science in Clinical Research and Review. 2024; 7(1): 93-99. https://doi.org/10.5281/zenodo.10610693
26. Callway E. Oxford COVID vaccine results puzzle scientists. Nature. 2020; 588:16-18.
27. Mascellino MT, et al. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy, and safety. Infect Drug Resist. 2021;14: 3459.
28. Garofalo M, et al. Prospects of replication-deficient adenovirus-based vaccine development against SARS-CoV-2. Vaccines. 2020; 8(2): 293.
29. Kurup D, Schnell MJ. SARS-CoV-2 vaccines–The biggest medical research project of the 21st century. Curr Opin Virol. 2021; 41: 1-6.
30. Angeli F, et al. SARS-CoV-2 vaccines: Lights and shadows. Eur J Intern Med. 2021; 83: 23-31.
31. Miller JM, et al. Guidelines for safe work practices in human and animal medical diagnostic laboratories. MMWR Surveill Summ. 2012;61(3):1-102.
32. Sarfaraz Ahmad, Ambreen Shoaib, Md. Sajid Ali, Md. Sarfaraz Alam, Nawazish Alam, Maksood Ali, Md. Ali Mujtaba, Ayaz Ahmad, Md. Salahuddin Ansari, Mohammad Daud Ali. Epidemiology, Risk, Myths, Pharmacotherapeutic Management and Socio- economic Burden due to Novel COVID-19: A Recent Update. Research Journal of Pharmacy and Technology. 2021; 14(4): 2308-5.
33. Subhashis Debnath, Runa Chakravorty, Donita Devi. COVID 19 and its management. Asian Journal of Pharmaceutical Research. 2021; 11(2): 117-1. doi: 10.52711/2231-5691.2021.00022
34. Jamdade PG, Jamdade SG. Side effects of Covishield vaccine on COVID-positive history family in India. World J Surg Infect. 2022; 1: 40-42.
35. Dhungana D, et al. Side effects of Covishield vaccine among frontline healthcare workers of a tertiary health care center. Med Rxiv. 2022. https://doi.org/10.1101/2022.06.06.22275888.
36. Zahid A. Johnson and Johnson Vaccine Update.
37. Amitkumar J. Vyas, Sinchan M. Patel, Ashok B. Patel, Ajay I. Patel, Nilesh K. Patel, Suuny Shah, Devang Sheth. Stability testing: An Essential study for Vaccine Formulation Development. Asian Journal of Pharmaceutical Research. 2022; 12(1): 29-6. doi: 10.52711/2231-5691.2022.00006
38. Swati G. Talele, Eknath D. Ahire, Khemchand R. Surana, Vijayraj N. Sonawane, Gokul S. Talele. Corona Virus Disease (COVID-19): A past and Present Prospective. Asian Journal of Pharmaceutical Research. 2022; 12(1): 45-3. doi: 10.52711/2231-5691.2022.00008
39. Jeet Kaur R, et al. Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database. Int J Gen Med. 2021;14: 3909-3927.
40. Huang KY, et al. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection. EMBO Mol Med. 2021; 13(1).
41. Shrestha Y, et al. COVID-19 Vaccine Authorized in India-A Mini Review. 2021.
42. Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269): 99-111.
43. Haritay S, et al. Waning of antibody response among vaccinees who received two doses of Covishield vaccine. J Glob Infect Dis. 2023; 15: 19-22.
44. Dandu H, et al. Humoral and cellular immune response in patients of liver cirrhosis and immunocompetent recipient of ChAdOx1 nCoV-19 Vaccine (Covishield). Clin Exp Med. 2024; 24(24). https://doi.org/10.1007/s10238-023-01258-z.
45. Nikhra V. Evolving COVID-19 Pandemic: The Lurking Dangers and Pillars of Hope.
46. Das S, et al. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res. 2022; 70(3): 289-315.
47. Jahan N, et al. Side effects following administration of the first dose of Oxford-AstraZeneca’s Covishield vaccine in Bangladesh: a cross-sectional study. Infect Dis Rep. 2021; 13(4): 888-901.
48. Analytica O. India’s vaccine roll-out faces key obstacles. Expert Briefings. 2021.
49. Jain T, et al. Post-vaccination side effects following the second dose of COVID-19 vaccine among health care workers. Int J Public Health. 2022; 11(2): 398-404.